News






Company OverviewCoronary Artery DiseaseTechnical ResourcesEmployment OpportunitiesWhat's New

Eminent Cardiologist Richard L. Popp, MD Joins Percardia Board of Directors

Merrimack, NH, June 25, 2001 /PRNewswire/ -- Percardia Inc., an early stage medical device company developing new therapeutic interventions for the treatment of coronary artery disease, is pleased to announce today the addition of Richard L. Popp, MD to its Board of Directors. Dr. Popp is currently Professor of Medicine at Stanford University. He received his undergraduate and medical degrees from Johns Hopkins University where he performed his internship and residency. He has been a clinical cardiologist for over 25 years. Dr. Popp began his career as an "invasive" cardiologist but focused his research on developing non-invasive methods for medical diagnosis and therapy.

In addition, he served as President of the American College of Cardiology (ACC) 1997-98 and has been a trustee of the ACC for many years. He has been President of the American Society of Echocardiography and the Association of University Cardiologists. He is the previous Chairman of the American Board of Internal Medicine's (ABIM) Cardiovascular Diseases Subspecialty Board and has been on the Executive Committee and the Board of Governors of the ABIM. He is a member of several honorary scientific associations including the American Society for Clinical Investigation and the Association of American Physicians.

Dr. Popp maintains a continuing interest in technology development for improved patient care. He has made significant contributions to the continuous improvement of ultrasonic diagnostic methods in areas including two-dimensional and three-dimensional echocardiography, Doppler ultrasound, color flow imaging, transesophageal and contrast echocardiography. He was one of the first to employ intravascular ultrasonic imaging. The diffusion of technology and new information into clinical practice is a special area of interest of Dr. Popp's. Government policy and regulation regarding medical devices and products took much of Dr. Popp's time during his year as ACC President.

Commenting on Dr. Popp's appointment, Jack Gill, Chairman of the Board stated, "We are pleased that Richard Popp has joined the Percardia Board of Directors. His enthusiasm for joining our Board reinforces the scientific importance of our VSTENT™ Myocardial Implant development activities in the emerging field of ventricular revascularization."

Ms. Briefs, CEO added, "We're thrilled to have someone of Richard Popp's stature and expertise on Percardia's Board of Directors. He brings a unique perspective to both scientific and business related issues as we move towards clinical experience with our new technology."

Additional information regarding the Company and its technology can be obtained at the company's website www.percardia.com.


Press Releases | Events

Company | Coronary Artery Disease | Resources | Employment | What's New

Percardia Inc.
Heron Cove Office Park
10 Al Paul Lane, Suite 202
Merrimack, NH 03054
© 2001 Percardia Inc.